Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic

Amber Tong

Senior Editor

Although Verve Therapeutics did not come up with a gene editing technology itself, its work applying base editing in cardiovascular diseases — going from launch to first-in-human dosing in just over three years — has caught the eye of Vertex.

Vertex is handing over $25 million in cash plus a $35 million equity investment to ally itself with Verve around an in vivo gene editing program for an undisclosed liver disease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force

Ver­tex taps Verve for gene edit­ing pact — buy­ing a chunk of shares — as Sek Kathire­san steers base edit­ing in­to clin­ic

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force